Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies-Reference-Cited by-同舟云学术

Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies

Published:2012-06 Issue:6 Volume:39 Page:510-513
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Hoenigl Martin,Raggam Reinhard B.,Salzer Helmut J.F.,Valentin Thomas,Valentin Angelika,Zollner-Schwetz Ines,Strohmeier Anna T.,Seeber Katharina,Wölfler Albert,Sill Heinz,Krause Robert

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. Underestimating the real burden of invasive fungal infections in hematopoietic stem cell transplant recipients?;Hoenigl;Clin Infect Dis,2010

2. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database;Kontoyiannis;Clin Infect Dis,2010

3. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update;Smith;Expert Rev Anti Infect Ther,2009

4. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update;Wilson;Mycopathologia,2009

5. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia;Al-Badriyeh;J Antimicrob Chemother,2010

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies;Journal of Chromatography B;2024-10

2. Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study;Clinical Microbiology and Infection;2024-07

3. Updated antimicrobial dosing recommendations for obese patients;Antimicrobial Agents and Chemotherapy;2024-05-02

4. Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices?;Expert Review of Clinical Pharmacology;2024-02-21

5. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft;Transplantation and Cellular Therapy;2024-02